The Patient Journey in Vitiligo

Vitiligo is a chronic, non-life-threatening skin disorder characterized by depigmented macules caused by the selective loss of melanocytes. Although its pathogenesis is multifactorial, encompassing autoimmune, genetic, and oxidative stress-related factors, it remains underdiagnosed, and patients frequently face delays in appropriate care. The visible nature of vitiligo, especially when it affects exposed areas like the face or hands, significantly impacts patients' psychological well-being and quality of life, often leading to social stigma, anxiety, and reduced self-esteem. A comprehensive understanding of the patient journey is crucial to improving outcomes.

The patient journey typically begins with the appearance of macules and psychological distress, often followed by unreliable self-directed research that delays proper diagnosis. Clinical examination supported by tools like Wood's lamp, dermoscopy, or biopsy enables correct classification, which is essential for treatment decisions. Disease severity is assessed using various scoring systems (e.g., VASI, BSA, VIDA), which guide therapy based on disease extent, activity, and patient-reported burden. Therapeutic strategies vary and may include topical corticosteroids or calcineurin inhibitors for localized disease, narrowband UVB phototherapy, or systemic corticosteroids for more extensive or active forms. Ruxolitinib cream, a JAK inhibitor, has recently emerged as the first approved targeted therapy for non-segmental vitiligo. In refractory cases, surgical interventions may be considered. The ideal care model involves a multidisciplinary unit coordinated by dermatologists and supported by psychologists, endocrinologists, and other specialists. This integrated approach addresses both clinical and psychosocial needs, facilitating timely diagnosis and personalized therapy.

Optimizing the patient journey through structured care networks and early specialist involvement is essential to improving quality of life and clinical outcomes. With the advent of novel treatments, healthcare systems must adapt to provide more coordinated, patient-centered care for individuals living with vitiligo.